{"id":"disitamab-vedotin-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Disitamab vedotin works by binding to the Trop-2 receptor on cancer cells, which leads to the internalization and degradation of the receptor, ultimately resulting in cell death. This mechanism is specific to cancer cells that express the Trop-2 receptor, minimizing harm to healthy cells.","oneSentence":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the Trop-2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:22.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic gastric adenocarcinoma"},{"name":"Locally advanced or metastatic esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06178159","phase":"PHASE2","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-11-28","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT05980481","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-04","conditions":"Gastric Cancer","enrollment":201},{"nctId":"NCT07142200","phase":"PHASE2","title":"A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-09-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":45},{"nctId":"NCT07100184","phase":"PHASE2","title":"RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-09-01","conditions":"HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT","enrollment":30},{"nctId":"NCT06957561","phase":"PHASE1, PHASE2","title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-30","conditions":"Bladder Cancer, Muscle-invasive Bladder Cancer","enrollment":30},{"nctId":"NCT06734182","phase":"PHASE2","title":"Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-06-22","conditions":"Non-small Cell Lung Cancer","enrollment":25},{"nctId":"NCT06663007","phase":"PHASE1, PHASE2","title":"RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-09-24","conditions":"Prostate Cancer, CDK12 Gene Mutation","enrollment":72},{"nctId":"NCT06378242","phase":"PHASE1, PHASE2","title":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-06-14","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":24},{"nctId":"NCT06227156","phase":"PHASE2","title":"Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-08","conditions":"Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT06389006","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-29","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT06221748","phase":"PHASE2, PHASE3","title":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-02-22","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT06227117","phase":"PHASE2","title":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-07-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT06155396","phase":"PHASE2","title":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-01-11","conditions":"Cervical Cancer","enrollment":116},{"nctId":"NCT05514158","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2022-09-28","conditions":"Gastric Cancer","enrollment":24},{"nctId":"NCT06074484","phase":"PHASE2","title":"A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-10","conditions":"Muscle Invasive Bladder Carcinoma","enrollment":36},{"nctId":"NCT06055153","phase":"PHASE1, PHASE2","title":"DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2023-09-30","conditions":"Esophageal Squamous Carcinoma, HER-2 Protein Overexpression","enrollment":20},{"nctId":"NCT05979740","phase":"PHASE2","title":"RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-08-01","conditions":"Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy","enrollment":6},{"nctId":"NCT06015113","phase":"NA","title":"Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Xi'an International Medical Center Hospital","startDate":"2023-09","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05955209","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-08-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT05723991","phase":"PHASE4","title":"Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Chunguang yang (101937)","startDate":"2022-09-28","conditions":"Radical Cystectomy, Urothelial Carcinoma","enrollment":36},{"nctId":"NCT05720533","phase":"PHASE2","title":"Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-03-01","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT05488353","phase":"PHASE4","title":"A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-01","conditions":"Bladder Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DV,RC48-ADC","RC48-ADC","DV,RC48"],"phase":"phase_2","status":"active","brandName":"Disitamab Vedotin Injection","genericName":"Disitamab Vedotin Injection","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the Trop-2 receptor. Used for Locally advanced or metastatic gastric adenocarcinoma, Locally advanced or metastatic esophageal squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}